Report from the 2nd Stem Cell Clonality and Genotoxicity Retreat

Molecular Therapy

Volumn 12, Issue 3, 2005, Pages 379-383

  Frederickson, Robert M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; CD34 ANTIGEN; GROWTH FACTOR RECEPTOR; INTEGRASE; PARVOVIRUS VECTOR; VIRUS VECTOR;

CELL BASED GENE THERAPY; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; CLONAL VARIATION; COMBINED IMMUNODEFICIENCY; CONFERENCE PAPER; DNA MODIFICATION; EPSTEIN BARR VIRUS; FANCONI ANEMIA; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; GENOTOXICITY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; LEUKEMOGENESIS; LYMPHOPROLIFERATIVE DISEASE; MUTAGENESIS; NONHUMAN; RISK BENEFIT ANALYSIS; SPUMA VIRUS; STEM CELL GENE THERAPY; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRUS CARCINOGENESIS;

HUMAN HERPESVIRUS 4; PARVOVIRUS; SPUMAVIRUS;

EID: 23844499570     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.07.694     Document Type: Conference Paper

References (17)

1. Kohn, D. B., et al. (2003). American Society of Gene Therapy (ASGT) Ad Hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol. Ther. 8: 180-187.
2. Baum, C., et al. (2004). Chance or Necessity? Insertional mutagenesis in gene therapy and it s consequences. Mol. Ther. 9: 9-13.
3. Baum, C., et al. 2005. A Balanced Decision? Regulatory Reaction to the "hird Case" Mol. Ther. 11: 819-20.
4. Davé U.P. et al. 2004 Gene Therapy Insertional Mutagenesis Insights. Science 303: 333.
5. Mitchell, R.S., et al. (2004). Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2: E234.
6. Izsvák, Z., and Ivics, Z. (2004). Sleeping Beauty transposition: Biology and applications for molecular therapy. Mol. Ther. 9: 147-56.
7. Yant, S. R., et al. (2005). High-resolution genome-wide mapping of transposon integration in mammals. Mol. Cell. Biol. 25: 2085-94.
8. Nakai, H., et al. (2005). Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J. Virol. 79: 3606-14.
9. De Palma, M., et al. (2005). Promoter Trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 105: 2307-15.
10. Themis, M., et al. (2005). Oncogenesis following delivery of a non-primate lentiviral genet herapy vector to fetal and neonatal mice. Mol. Ther. 12: In press.
11. Kustikova, O., et al. (2005). Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308: 1171-4.
12. Modlich, U., et al. (2005). Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 105: 4235-46.
13. Kiem, H.-P,. et al. (2004). Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: No progression to clonal hematopoiesis or leukemia. Mol. Ther. 9: 389-95.
14. Hematti, P., et al. (2004). Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol. 2: E423.
15. Schmidt, M., et al. (2005). Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. Blood 105: 2699-2706.
16. Gaspar, H. B., et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364: 2181-7.
17. Groth A. C., and Calos, M. P. (2004). Phage integrases: Biology and applications. J. Mol. Biol. 335: 667-78.